RAS Quantification in Patients With Aliskiren or Candesartan

NCT01827202 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Hypertension
Chronic Kidney Disease
Proteinuria

Interventions

OTHER: RAS blockade discontinuation
DRUG: Aliskiren
DRUG: Candesartan

Sponsor

Medical University of Vienna